The impact of metabolic syndrome on the clinical course of acute myocardial infarction
Abstract
Myocardial infarction (MI) continues to be one of the most important problems of modern cardiology in Russia due to maintaining a sustainable morbidity and mortality. Of particular interest are the growth of the relationship of cardiovascular disease and myocardial infarction with the accumulation in the population of persons with obesity and other metabolic disorders. Now to have a clear view of the relationship of metabolic syndrome and cardiovascular disease. Mechanisms of metabolic syndrome, including insulin resistance, hyperinsulinemia, chronic inflammation, run and maintain a high level atherogenesis, endothelial dysfunction, provoke instability of coronary plaque, thrombus formation processes. This is a strong incentive to continue research in this area, which should help to find new ways of preventing MS to reduce the possible coronary risk, affect the outcome of treatment and to determine the characteristics of MI, developed on the background of MS.
About the Authors
T. A. Mal’kova
Ministry of Health and Social Development of Russia
Russian Federation
Russian Federation
State budgetary educational institution of higher professional education Novosibirsk State Medical University
630091
Red Avenue, 52
Novosibirsk
A. D. Kuimov
Ministry of Health and Social Development of Russia
Russian Federation
Russian Federation
State budgetary educational institution of higher professional education Novosibirsk State Medical University
630091
Red Avenue, 52
Novosibirsk
M. I. Voevoda
RAMS
Russian Federation
Russian Federation
SB RAMS
Establishment of the Russian Academy of Medical Sciences Research Institute of Therapy
630089
st. Boris Bogatkov, 175/1
Novosibirsk
References
1. Богова О. Т. Инфаркт миокарда. Воспаление и прогноз / О. Т. Богова, И. И. Чукаева // Рус. кардиол. журн. – 2003. – № 4 (42). – С. 95–97.
2. Оганов Р. Г. Ишемическая болезнь сердца / Р. Г. Оганов, Ю. М. Поздняков, В. С. Волков. – М.: Синергия, 2002.
3. Сыркин А. Л. Инфаркт миокарда / А. Л. Сыркин. – М.: Медицинское информационное агентство, 2005. – 466 с.
4. Чазов Е. И. Инфаркт миокарда – прошлое, настоящее и некоторые проблемы будущего / Е. И. Чазов // Сердце. – 2002. – Т. 1, № 1 (1). – С. 6–8.
5. Диденко В. А. Метаболический синдром X: история вопроса и этиопатогенез / В. А. Диденко // Лабораторная медицина. – 2005. – № 2. – С. 33–40.
6. Дороднева Е. Ф. Метаболический синдром / Е. Ф. Дороднева, Т. А. Пугачева, И. В. Медведева // Терапевт. арх. – 2002. – Т. 74, № 10. – С. 7–12.
7. Котовская Ю. В. Метаболический синдром: прогностическое значение и современные подходы к комплексной терапии / Ю. В. Котовская // Сердце. – 2005. – Т. 4, № 5 (23). – С. 236–242.
8. Чазова И. Е. Метаболический синдром / И. Е. Чазова, В. Б. Мычка. – М.: Медиа Медика, 2004.
9. Чазова И. Е. Основные принципы диагностики и лечения метаболического синдрома / И. Е. Чазова, В. Б. Мычка // Сердце. – 2005. – Т. 4, № 5 (23). – С. 232–235.
10. Алмазов В. А. Метаболический сердечно-сосудистый синдром / В. А. Алмазов [и др.] – СПб.: Изд-во СПбГМУ, 1999.
11. Гинзбург М. М. Ожирение. Влияние на развитие метаболического синдрома. Профилактика и лечение / М. М. Гинзбург, Н. Н. Крюков. – М.: Медпрактика, 2002.
12. Гинзбург М. М. Ожирение и метаболический синдром. Влияние на состояние здоровья, профилактика и лечение / М. М. Гинзбург, Г. С. Козупица, Н. Н. Крюков. – Самара: «Парус», 2000.
13. Reaven G. Role of insulin resistance in human disease // Diabetes. 1988. Vol. 37. P. 1595–1607.
14. Ройтберг Г. Е. Метаболический синдром / Г. Е. Ройтберг. – М.: МЕД-пресс-информ, 2007.
15. Перова Н. В. Метаболический синдром: патогенетические взаимосвязи и направления коррекции / Н. В. Перова, В. А. Метельская, Р. Г. Оганов // Кардиология. – 2001. – Т. 41, № 3. – С. 4–9.
16. Жернакова Ю. В. Связь числа компонентов метаболического синдрома с распространенностью и выраженностью поражения органов-мишеней / Ю. В. Жернакова [и др.] // Системные гипертензии. – 2011. – Т. 8, № 2. – С. 50–54.
17. Ford E. S., Giles W. H., Dietz W. H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey // JAMA. 2002. Vol. 16, N 287 (3). Р. 356–359.
18. Никитин Ю. П. Распространенность компонентов метаболического синдрома X в неорганизованной городской популяции (эпидемиологическое исследование) / Ю. П. Никитин, Г. Р. Казека, Г. И. Симонова // Кардиология. – 2001. – № 9. – С. 37–40.
19. Lakka H. M. The metabolic syndrome and total cardiovascular disease mortality in middle – agen men // JAMA. 2002. Vol. 28, N 21. P. 2709–2716.
20. Isomaa B. et al. Botnia study // Diabetes Care. 2005. Р. 683–689.
21. McNell A., Rosamond W., Girman C., Golden S. et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study // Diabetes Care. 2005. Vol. 28 (2). P. 385–390.
22. Vogelzang A. D., Zijlstra F. Glucose metabolism and acute myocardial infarction // Europ. Heart J. 2006. Vol. 27, N 11. P. 1264–1265.
23. Zeller M. et al. Prevalence and impact of metabolic syndrome on Hospital Outcomes in acute myocardial infarction // Arch. Intern. Med. 2005. Vol. 165. P. 1192–1198.
24. Turhan H., Yetkin E. Poor in-hospital outcome in young women with acute myocardial infarction. Does metabolic syndrome play a role // Int. J. of Cardiology. 2006. Vol. 112. Р. 257–258.
25. Sattar N. et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of scotland coronary prevention study // Circulation. 2003. Vol. 10. P. 408–414.
26. Corrado E. et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions. A 5-Year Follow-Up Study // Stroke. 2006. Vol. 37. P. 482–486.
27. Schwartz R. S. Detecting vulnerable plaque using peripheral blood: inflammatory and cellular markers // J. Interv Cardiol. 2003. Vol. 16, N 3. P. 231–242.
28. Levantesi G. et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction // J. Amer. Coll. Cardiol. 2005. Vol. 46. P. 277–283.
29. Clavijo L. C. et al. Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications // Cardiovascular Revascularization Medicine. 2006. Vol. 7. P. 7–11.
30. Thim T. et al. Size of myocardial infarction induced by ischaemia / reperfusion is unaltered in rats with metabolic syndrome // Clinical Science. 2006. Vol. 110. P. 665–671.
31. Митьковская Н. П. Течение инфаркта миокарда при неблагоприятной кластеризации факторов риска / Н. П. Митьковская, Т. В. Статкевич // Сиб. мед. журн. – 2010. – № 2. – С. 52–53.
32. Chung E. H. et al. Prevalence of metabolic syndrome in patients <45 years of age with acute myocardial infarction having percutaneous coronary intervention // Am. J. Cardiol. 2007. Vol. 5. P. 1052–1055.
33. Tartan Z. et al. Metabolic syndrome is a predictor for an ECG sign of no-reflow after primary PCI in patients with acute ST-elevation myocardial infarction // Nutrition, Metabolism & Cardiovascular Diseases. 2008. Vol. 18. P. 441–447.
34. Dong J. et al. Early resolution of ST-segment elevation correlates with myocardial salvage assessed by Tc-99m sestamibiscintigraphy in patients with acute myocardial infarction after mechanical or thrombolytic reperfusion therapy // Circulation. 2002. Vol. 105. P. 2946–2949.
35. De Lemos J. A. et al. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy: Thrombolysis in Myocardial Infarction (TIMI) 14 investigators // Am. J. Cardiol. 2000. Vol. 85. P. 299–304.
36. Schroder R. et al. Extent of early ST-segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens: a substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial // J. Am. Coll. Cardiol. 1995. Vol. 26. P. 1657–1664.
37. Rana J. S. et al. Metabolic syndrome and risk of restenosis in patients undergoing precutaneous coronary intervention // Diabetes Care. 2005. Vol. 28. P. 873–877.
38. Hoffmann R. et al. Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents // Am. J. Cardiol. 2007. Vol. 100. P. 1347–1352.
39. Canibusa P. et al. Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation // Metabolism Clinical and Experimental. 2008. Vol. 57. P. 593–597.
40. Tommasino A. et al. Impact of metabolic syndrome on angiographic and clinical outcome after stenting // Am. J. Cardiol. 2008. Vol. 10. P. 1016.
41. Piatti P. M. et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting // Circulation. 2003. Vol. 108. P. 2074–2081.
42. Nishioa K. et al. Insulin resistance as a predictor for restenosis after coronary stenting // Int. J. Cardiol. 2005. Vol. 103. P. 128–134.
Review
For citations:
Mal’kova T.A., Kuimov A.D., Voevoda M.I. The impact of metabolic syndrome on the clinical course of acute myocardial infarction. Ateroscleroz. 2012;8(2):21-26. (In Russ.)
Views:
213
Email this article 